A human mAb 1339 targeting interleukin-6 (IL-6) is being developed for MM.(41) The targeting of soluble ligands that affect bone biology by using mAbs such as the anti-RANKL mAb denosumab(42) and the anti-DKK1 mAb BHQ880(43) is promising, not only for preserving bone integrity but also for treating MM.(34) In January 2012, denosumab was approved in Japan for the treatment of bone complications caused by MM.(42). Here, TNFSF11 is linked to Miyoshi myopathy.